TickerFacts.

Myriad Genetics Inc (MYGN): Total Assets

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2017-06-30 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$706.60M
As of 2025-12-31
$638.90M
As of 2026-06-30
-16.2%
3-year compound annual growth
-13.0%
5-year compound annual growth
$1.56B2010-06-30: $593.85M2011-06-30: $610.83M2012-06-30: $690.63M2013-06-30: $803.82M2014-06-30: $823.80M2015-06-30: $766.20M2016-06-30: $880.50M2017-06-30: $1.21B2018-06-30: $1.18B2019-06-30: $1.56B2020-06-30: $1.40B2020-12-31: $1.42B2021-12-31: $1.32B2022-12-31: $1.20B2023-12-31: $1.15B2024-12-31: $1.03B2025-12-31: $706.60M$706.60M
2010-06-30 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$706.60M-31.2%2026-02-24, Balance as of period end
2024-12-31$1.03B-10.4%2026-02-24, Balance as of period end
2023-12-31$1.15B-4.4%2025-02-28, Balance as of period end
2022-12-31$1.20B-9.2%2024-02-28, Balance as of period end
2021-12-31$1.32B-6.9%2023-03-01, Balance as of period end
2020-12-31$1.42Bn/a2022-02-25, Balance as of period end
2020-06-30$1.40B-10.1%2020-08-13, Balance as of period end
2019-06-30$1.56B+33.0%2020-08-13, Balance as of period end
2018-06-30$1.18B-2.8%2019-08-13, Balance as of period end
2017-06-30$1.21Bn/c2018-08-24, Balance as of period end
2016-06-30$880.50M+14.9%2017-08-09, Balance as of period end
2015-06-30$766.20M-7.0%2016-08-10, Balance as of period end
2014-06-30$823.80M+2.5%2015-08-12, Balance as of period end
2013-06-30$803.82M+16.4%2014-08-13, Balance as of period end
2012-06-30$690.63M+13.1%2013-08-14, Balance as of period end
2011-06-30$610.83M+2.9%2012-08-15, Balance as of period end
2010-06-30$593.85Mn/a2011-08-15, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Myriad Genetics Inc (MYGN)2025-12-31$706.60M-31.2%
Neogen Corp (NEOG)2026-05-31$3.35B-2.8%
Lantheus Holdings, Inc. (LNTH)2025-12-31$2.23B+12.5%
QuidelOrtho Corp (QDEL)2025-12-28$5.77B-10.2%
Idexx Laboratories Inc (IDXX)2025-12-31$3.35B+1.7%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$842.13M-29.3%
Alpha Teknova, Inc. (TKNO)2025-12-31$103.58M-12.8%
Immucell Corp (ICCC)2025-12-31$42.53M-5.7%
Aspira Women's Health Inc. (AWHL)2025-12-31$5.46M-0.6%

Compare MYGN, NEOG, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗